viewTetra Bio-Pharma

Tetra Bio-Pharma reveals promising results in inflammatory lung injury treatment, forms new collaboration

Tetra Bio-Pharma Inc.(TSX: TBP) (OTCQB: TBPMF) CEO Guy Chamberland tells Proactive the biotechnology company it has revealed promising results of an experimental study with its investigational new drug ARDS-003 in a model of lung injury.

Chamberland says the group will soon be submitting the application for a Phase I clinical trial to demonstrate safety in healthy volunteers before initiating studies in patients with COVID-19.

What's more, the company has also signed a research collaboration agreement with Targeted Pharmaceutical and George Mason University to evaluate how ARDS-003 can prevent and treat the coronavirus in animals.

Quick facts: Tetra Bio-Pharma

Price: 0.195 CAD

Market: TSX
Market Cap: $54.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...


Tetra Bio-Pharma makes progress with inhaled THC-based drug in meeting with...

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive the group it held a Type B meeting with the FDA for an inhaled THC-based innovative drug for the treatment of chemotherapy-induced nausea and vomiting (CINV). Chamberland says new drug will be part its...

on 16/12/20

2 min read